Adicet Bio Inc (ACET) Stock Price, Quote & News

Company Profile

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 503 9095

Website: www.adicetbio.com

Address:

131 Dartmouth Street, 3rd Floor, Boston, United States

AGC_Trader Aug. 19 at 2:16 PM

$ACET needs Volume...

0 · Reply

Malandrosky Aug. 19 at 1:34 PM

$ACET halted?

1 · Reply

Peterson28 Aug. 18 at 2:48 PM

$ACET Rookie trader? Pre and post market can go up or down 20% with just one share traded. Very illiquid trading hours. That’s how MM manipulates to make retail believe in one direction and then trade against it to exit or open positions.

1 · Reply

Bing25 Aug. 18 at 1:53 PM

$ACET why this so crazy price action in the premarket? You guys seeing this?

1 · Reply

BullyMCBullface Aug. 11 at 10:00 PM

$ACET listened to the talk in my car; this guy knows where he is talking about and was a confident speaker with very specific and clear answers. Let’s hope he doesn’t believe in fairytales

0 · Reply

BioTechChap Aug. 11 at 6:15 PM

$ACET CMO leaves the company disorderly at the cusp of a major inflection point. SMH, as bearish as it can get. Of course no mention of this transition during today's Canaccord conference session.

0 · Reply

aletz Aug. 7 at 6:49 PM

$ACET 2H 2026, a bunch of catalysts are coming after a long wait. It'll be exciting to see the real efficacy data and regulatory pathway. Started a long position yesterday. $INAB , another gamma delta t cel engager currently pending preclinical data. SP beaten down lately.

0 · Reply

91aprilfool Aug. 7 at 5:35 PM

$ACET @metalcook nice try! The previous Chief Medical Officer, Dr. Francesco Galimi, left when his tenure concluded in December 2024. He was succeeded by Dr. Julie Maltzman, who was appointed as the new Chief Medical Officer effective January 13, 2025.

1 · Reply

metalcook Aug. 6 at 5:46 PM

$ACET so CMO left and management has delayed data. Whats up with the phase 3 plans? Seems clearly a problem here. These red flags are classic signals of bad management. I would guess durability is a problem

1 · Reply

anachartanalyst Aug. 6 at 2:03 PM

$ACET https://anachart.com/wp-content/uploads/2026/08/1786024972_soc-img.jpg

0 · Reply

Adicet Bio Transcript: Canaccord Genuity's 46th Annual Growth Conference

2026-08-06T10:53:16.000Z - 13 days ago

Market Cap	81.82M
Revenue (ttm)	0.00
Net Income (ttm)	-116.80M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	25,733
Avg Vol	87,290
Day's Range	N/A - N/A
Shares Out	9.36M
Stochastic %K	94%
Beta	1.60
Analysts	Strong Sell
Price Target	$33.17